5 Endometrial Cancer Clinical Trials in Little Rock, AR (2026)

Q: How do I join a clinical trial in Little Rock?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you.

Recruiting Endometrial Cancer Studies in Little Rock

NCT06989112Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...

Little Rock, ARPHASE3600 participantsAstraZeneca

View Study Details

NCT05548296Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....

Little Rock, ARPHASE2350 participantsAcrivon Therapeutics

View Study Details

NCT07198074Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizuma...

Little Rock, ARPHASE3255 participantsNational Cancer Institute (NCI)

View Study Details

NCT07444814Recruiting

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with a...

Little Rock, ARPHASE1226 participantsWhitehawk Therapeutics, Inc.

View Study Details

NCT05997017Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer...

Little Rock, ARPHASE229 participantsAadi Bioscience, Inc.

View Study Details

About Endometrial Cancer Clinical Trials in Little Rock

Endometrial cancer begins in the lining of the uterus and is the most common gynecologic cancer. It is often detected early due to abnormal bleeding symptoms. Treatment typically involves surgery, with radiation, chemotherapy, or hormone therapy for advanced cases.

There are currently 5 endometrial cancer clinical trials recruiting participants in Little Rock, AR. These studies are seeking a combined 1,460 participants. Research is being sponsored by AstraZeneca, Acrivon Therapeutics, National Cancer Institute (NCI) and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Endometrial Cancer Clinical Trials in Little Rock — FAQ

Are there endometrial cancer clinical trials in Little Rock?

Yes, there are 5 endometrial cancer clinical trials currently recruiting in Little Rock, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Little Rock?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.

Are clinical trials in Little Rock free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.

What endometrial cancer treatments are being tested?

The 5 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for endometrial cancer.

Data updated July 17, 2026 from ClinicalTrials.gov